Literature DB >> 22056472

Differential regulation of RGS proteins in the prefrontal cortex of short- and long-term human opiate abusers.

Guadalupe Rivero1, Ane M Gabilondo, M Julia García-Fuster, Romano La Harpe, Jesús A García-Sevilla, J Javier Meana.   

Abstract

Opiate addiction is characterized by drug tolerance and dependence which involve adaptive changes in μ-opioid receptors (MORs) signaling. Regulators of G-protein signaling RGS9, RGS4 and RGS10 proteins negatively regulate G(αi/o) protein activity modulating MOR function. An important role of RGS proteins in drug addiction has been described but the status of RGS proteins in human brain of opiate addicts remains unknown. The present study evaluated the immunoreactivity levels of RGS4, RGS9 and RGS10 proteins in prefrontal cortex of short- (n = 15) and long-term (n = 21) opiate abusers and in matched control subjects. RGS4 protein was not altered in short-term opiate abusers but, in long-term abusers it was significantly up-regulated (Δ = 29 ± 6%). RGS10 protein expression was significantly decreased in short-term (Δ = -42 ± 7%) but remained unaltered in long-term opiate abusers. RGS9 protein levels in opiate abusers did not differ from matched controls either in the short-term or in the long-term opiate abuser groups. RGS4, RGS9 and RGS10 levels were also studied in brains (frontal cortex) of rats submitted to acute and chronic morphine treatment and to spontaneous and naloxone-precipitated opiate withdrawal. Chronic morphine treatment in rats was associated with an increase in RGS4 protein immunoreactivity (Δ = 28 ± 7%), which persisted in spontaneous (Δ = 35 ± 8%) and naloxone-precipitated withdrawal (Δ = 30 ± 9%) without significant changes in RGS9 and RGS10 proteins. The specific modulation of RGS4 and RGS10 protein expression observed in the prefrontal cortex of opiate abusers might be relevant in the neurobiology of opiate tolerance, dependence and withdrawal. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056472     DOI: 10.1016/j.neuropharm.2011.10.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

Review 1.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 2.  Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.

Authors:  Mohammed Alqinyah; Shelley B Hooks
Journal:  Cell Signal       Date:  2017-10-16       Impact factor: 4.315

3.  MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 expression in colonic smooth muscle cells.

Authors:  Yonggang Zhang; Fang Li; Shu Liu; Hong Wang; Sunila Mahavadi; Karnam S Murthy; Kamel Khalili; Wenhui Hu
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

4.  Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction.

Authors:  Cielito C Reyes-Gibby; Christine Yuan; Jian Wang; Sai-Ching J Yeung; Sanjay Shete
Journal:  BMC Syst Biol       Date:  2015-06-05

5.  Splicing factor transformer-2β (Tra2β) regulates the expression of regulator of G protein signaling 4 (RGS4) gene and is induced by morphine.

Authors:  Shu-Jing Li; Ya Li; Shi-chao Cui; Yao Qi; Jing-Jing Zhao; Xiao-Yan Liu; Ping Xu; Xian-Hua Chen
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

6.  The First Pilot Genome-Wide Gene-Environment Study of Depression in the Japanese Population.

Authors:  Takeshi Otowa; Yoshiya Kawamura; Akizumi Tsutsumi; Norito Kawakami; Chiemi Kan; Takafumi Shimada; Tadashi Umekage; Kiyoto Kasai; Katsushi Tokunaga; Tsukasa Sasaki
Journal:  PLoS One       Date:  2016-08-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.